Lyell Immunopharma (LYEL) EBIT Margin (2020 - 2026)

Lyell Immunopharma has reported EBIT Margin for 7 years, with the latest figure at 2213050.0% in Q1 2026.

• Quarterly EBIT Margin fell 139352143.0% year-over-year to 2213050.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 826767.74% (down 27208005.0% YoY) and the FY2025 annual result came in at 748344.44%, down 16022149.0% from the prior year.
• EBIT Margin slipped to 2213050.0% in Q1 2026 per LYEL's latest filing, from 2127400.0% in the prior quarter.
• Over five years, EBIT Margin peaked at 30.55% in Q4 2022 and troughed at 2214566.67% in Q3 2022.
• A 5-year average of 793232.29% and a median of 396369.23% in 2024 frame the typical range for EBIT Margin.
• The sharpest annual moves came in 2022 and 2023: EBIT Margin plunged 221278224 bps in 2022, then surged 197841067 bps in 2023.
• Over 5 years, EBIT Margin stood at 30.55% in 2022, then plunged by 1498065 bps to 457753.85% in 2023, then sank by 299 bps to 1828609.09% in 2024, then retreated by 16 bps to 2127400.0% in 2025, then fell by 4 bps to 2213050.0% in 2026.
• According to Business Quant data, EBIT Margin over the past three periods registered 2213050.0%, 2127400.0%, and 248353.33% for Q1 2026, Q4 2025, and Q3 2025 respectively.